Menu

Every-other-day dosing for patients on the go

Routine prophylaxis: 85 U/kg every other day1
Every-other-day dosing for patients on the go
FEIBA [Anti-Inhibitor Coagulant Complex] is the only FDA-approved prophylactic treatment for people with hemophilia A and B with inhibitors.1

FEIBA Guidelines for Dosing

Patients with inhibitors present a difficult clinical challenge. Bypassing agents, such as FEIBA, play an important role in the management of bleeds in patients with inhibitors.1,18,19

Use this guide to help when determining the appropriate dose for your patients based on weight, dosing schedule, and type of bleeding episode.

1. Select your patient’s body weight

Select
  • 22 lb (10 kg)
  • 33 lb (15 kg)
  • 44 lb (20 kg)
  • 55 lb (25 kg)
  • 66 lb (30 kg)
  • 77 lb (35 kg)
  • 88 lb (40 kg)
  • 99 lb (45 kg)
  • 110 lb (50 kg)
  • 121 lb (55 kg)
  • 132 lb (60 kg)
  • 143 lb (65 kg)
  • 154 lb (70 kg)
  • 165 lb (75 kg)
  • 176 lb (80 kg)
  • 187 lb (85 kg)
  • 198 lb (90 kg)
  • 209 lb (95 kg)
  • 220 lb (100 kg)
  • 231 lb (105 kg)
  • 242 lb (110 kg)
  • 253 lb (115 kg)
  • 264 lb (120 kg)
  • 275 lb (125 kg)
  • 286 lb (130 kg)
  • 297 lb (135 kg)
  • 308 lb (140 kg)

2. Select dosing schedule

  • Routine prophylaxis
  • Control and prevention
  • Perioperative management

3. Select type of bleeding episode

  • Preoperative
  • Postoperative
  • Joint hemorrhage
  • Mucous membrane bleeding
  • Soft tissue hemorrhage (e.g., retroperitoneal bleeding)
  • Other severe hemorrhage (e.g., CNS bleeds)

Dose range: 50 U/2.2 lb (50 U/kg) - 100 U/2.2 lb (100 U/kg)

Total FEIBA units range: to

Dose: 85 U/2.2 lb (85 U/kg)

Total FEIBA units:

Frequency of doses (hours): 6

Duration of therapy: At least 1 day or until bleeding is resolved

Do not exceed a single dose of 100 units per kg body weight and a daily dose of 200 units per kg body weight.1

Healthcare professionals are ultimately responsible for determining the appropriate dose for each patient based on patient examination, characteristics, and medical judgment.

Dosage and duration of treatment depend on the location and extent of bleeding and the patient’s clinical condition. Careful monitoring of replacement therapy is necessary in cases of major surgery or life-threatening bleeding episodes.1

Base the dose and frequency of FEIBA on the individual clinical response. Clinical response to treatment with FEIBA may vary by patient and may not correlate with the patient’s inhibitor titer.1

Do not exceed a single dose of 100 units per kg body weight and a daily dose of 200 units per kg body weight.1

Selected Important Risk Information for FEIBA [Anti-Inhibitor Coagulant Complex]

WARNING: EMBOLIC AND THROMBOTIC EVENTS

  • Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA, particularly following the administration of high doses (above 200 units per kg per day) and/or in patients with thrombotic risk factors.
  • Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events.

CONTRAINDICATIONS

FEIBA is contraindicated in patients with:

  • History of anaphylactic or severe hypersensitivity reactions to FEIBA or any of its components, including factors of the kinin generating system
  • Disseminated intravascular coagulation (DIC)
  • Acute thrombosis or embolism (including myocardial infarction)

WARNINGS AND PRECAUTIONS

Thromboembolic events (including venous thrombosis, pulmonary embolism, myocardial infarction, and stroke) can occur, particularly following the administration of high doses (>200 units/kg/day) and/or in patients with thrombotic risk factors.

Administration

Get information about the BAXJECT® II Hi-Flow Needleless Transfer Device and available dosage strengths.

Learn More

Efficacy and Safety Data

Find out how FEIBA helped patients with hemophilia A or B with inhibitors in a clinical trial.

See the Data
See LessMore

Indications for Feiba

FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes

Detailed Important Risk Information

WARNING: EMBOLIC AND THROMBOTIC EVENTS

  • Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA,

Indications for Feiba

FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in
hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes
  • Perioperative management
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

FEIBA is not indicated for the treatment of bleeding episodes resulting from...

Detailed Important Risk Information

WARNING: EMBOLIC AND THROMBOTIC EVENTS

  • Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA, particularly following the administration of high doses (above 200 units per kg per day) and/or in patients with thrombotic risk factors.
  • Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events.
;